FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and concerns a method of treating or modulating malignant cell population growth involving the introduction into an individual suffering a malignant tumour of an effective amount of lenalidomide, at least one corticosteroid, and at least one immunoconjugate, wherein the immunoconjugate contains at least one cell-binding agent which binds CD56, and at least one antimitotic agent wherein the cell-binding agent is an antibody, a one-chain antibody or an antigen-binding antibody fragment.
EFFECT: invention provides a therapeutic synergy or improved therapeutic index in cancer therapy as compared with separately used immunocojugate, chemotherapeutic agent used separately or in a combination with the other chemotherapeutic agent with no immunoconjugate added.
53 cl, 7 ex, 8 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
| APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 | 2012 |
|
RU2632108C2 |
| METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT | 2008 |
|
RU2486203C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM | 2008 |
|
RU2547939C2 |
| COMPOSITIONS AND METHODS FOR TREATING DISEASE | 2007 |
|
RU2482877C2 |
| ANTIBODIES TO FcRH5, THEIR IMMUNOCONJUGATES AND METHODS OF THEIR USE | 2010 |
|
RU2583270C2 |
| CD138-TARGETED CELL AGENTS AND USING THEM | 2008 |
|
RU2537265C2 |
| ANTI-FcRH5 ANTIBODIES, IMMUNOCONJUGATES THEREOF AND METHODS FOR USE THEREOF | 2010 |
|
RU2587621C2 |
| IMPROVED METHODS FOR TREATING TUMOURS | 2007 |
|
RU2481853C2 |
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
